BioNTech will cut 1,860 jobs across Germany and Singapore while launching a $1 billion share buyback program. The restructuring follows the exit of co-founders Ugur Sahin and Oezlem Tuereci to launch a new venture. Investors are tracking the biotech's pivot as it hands COVID-19 vaccine production to PFIZER INC.

Production Shift and Site Closures